XERIS BIOPHARMA HOLDINGS, INC. (XERS) Return on equity 2020–2025
XERIS BIOPHARMA HOLDINGS, INC. (XERS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
4.0%FY2025 · since FY2020: -270.0% → 4.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 4.0% | — |
| FY2022 | -209.5% | -80.6 pp |
| FY2021 | -128.9% | +141.1 pp |
| FY2020 | -270.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More XERS financial trends
XERS RevenueXERS Net incomeXERS Net marginXERS Gross profitXERS Gross marginXERS Operating incomeXERS Operating marginXERS Operating cash flowXERS Free cash flowXERS Capital expendituresXERS Stock buybacksXERS Dividends paidXERS Total assetsXERS Total liabilitiesXERS Shareholders’ equityXERS overview →